vs
Side-by-side financial comparison of Hologic (HOLX) and VinFast Auto Ltd. (VFS). Click either name above to swap in a different company.
Hologic is the larger business by last-quarter revenue ($1.0B vs $718.6M, roughly 1.5× VinFast Auto Ltd.). Hologic runs the higher net margin — 17.1% vs -2.8%, a 19.9% gap on every dollar of revenue.
Hologic, Inc. is an American medical technology company primarily focused on women's health; it sells medical devices for diagnostics, surgery, and medical imaging.
VinFast Auto Ltd. is a Vietnamese multinational automotive company founded by Vingroup, one of the largest private conglomerates in Vietnam that was founded by Phạm Nhật Vượng.
HOLX vs VFS — Head-to-Head
Income Statement — Q1 FY2026 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.0B | $718.6M |
| Net Profit | $179.1M | $-20.0M |
| Gross Margin | 56.0% | — |
| Operating Margin | 22.6% | -96.1% |
| Net Margin | 17.1% | -2.8% |
| Revenue YoY | 2.5% | — |
| Net Profit YoY | -10.9% | — |
| EPS (diluted) | $0.79 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.0B | — | ||
| Q3 25 | $1.0B | $718.6M | ||
| Q2 25 | $1.0B | $663.0M | ||
| Q1 25 | $1.0B | $656.5M | ||
| Q4 24 | $1.0B | — | ||
| Q3 24 | $988.0M | $511.6M | ||
| Q2 24 | $1.0B | — | ||
| Q1 24 | $1.0B | $302.6M |
| Q4 25 | $179.1M | — | ||
| Q3 25 | $187.2M | $-20.0M | ||
| Q2 25 | $194.9M | $-51.8M | ||
| Q1 25 | $-17.4M | $-26.1M | ||
| Q4 24 | $201.0M | — | ||
| Q3 24 | $178.6M | $-10.4M | ||
| Q2 24 | $194.5M | — | ||
| Q1 24 | $169.9M | $-618.3M |
| Q4 25 | 56.0% | — | ||
| Q3 25 | 55.6% | — | ||
| Q2 25 | 56.3% | — | ||
| Q1 25 | 37.5% | — | ||
| Q4 24 | 56.8% | — | ||
| Q3 24 | 56.4% | — | ||
| Q2 24 | 55.4% | — | ||
| Q1 24 | 53.3% | — |
| Q4 25 | 22.6% | — | ||
| Q3 25 | 22.6% | -96.1% | ||
| Q2 25 | 24.9% | -79.0% | ||
| Q1 25 | -0.7% | -74.0% | ||
| Q4 24 | 22.5% | — | ||
| Q3 24 | 23.3% | -65.9% | ||
| Q2 24 | 24.1% | — | ||
| Q1 24 | 20.7% | -139.4% |
| Q4 25 | 17.1% | — | ||
| Q3 25 | 17.8% | -2.8% | ||
| Q2 25 | 19.0% | -7.8% | ||
| Q1 25 | -1.7% | -4.0% | ||
| Q4 24 | 19.7% | — | ||
| Q3 24 | 18.1% | -2.0% | ||
| Q2 24 | 19.2% | — | ||
| Q1 24 | 16.7% | -204.3% |
| Q4 25 | $0.79 | — | ||
| Q3 25 | $0.84 | — | ||
| Q2 25 | $0.86 | — | ||
| Q1 25 | $-0.08 | — | ||
| Q4 24 | $0.87 | — | ||
| Q3 24 | $0.75 | — | ||
| Q2 24 | $0.82 | — | ||
| Q1 24 | $0.72 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.4B | $8.8M |
| Total DebtLower is stronger | $2.5B | — |
| Stockholders' EquityBook value | $5.2B | — |
| Total Assets | $9.2B | $183.2M |
| Debt / EquityLower = less leverage | 0.48× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.4B | — | ||
| Q3 25 | $2.2B | $8.8M | ||
| Q2 25 | $1.9B | $650.0M | ||
| Q1 25 | $1.6B | $2.4M | ||
| Q4 24 | $2.0B | — | ||
| Q3 24 | $2.3B | $1.9M | ||
| Q2 24 | $2.4B | — | ||
| Q1 24 | $2.2B | $3.0M |
| Q4 25 | $2.5B | — | ||
| Q3 25 | $2.5B | — | ||
| Q2 25 | $2.5B | — | ||
| Q1 25 | $2.5B | — | ||
| Q4 24 | $2.5B | — | ||
| Q3 24 | $2.5B | — | ||
| Q2 24 | $2.5B | — | ||
| Q1 24 | $2.6B | — |
| Q4 25 | $5.2B | — | ||
| Q3 25 | $5.0B | — | ||
| Q2 25 | $4.8B | $-7.2B | ||
| Q1 25 | $4.6B | — | ||
| Q4 24 | $4.8B | — | ||
| Q3 24 | $5.1B | — | ||
| Q2 24 | $5.0B | — | ||
| Q1 24 | $4.8B | — |
| Q4 25 | $9.2B | — | ||
| Q3 25 | $9.0B | $183.2M | ||
| Q2 25 | $8.8B | $7.2B | ||
| Q1 25 | $8.5B | $158.2M | ||
| Q4 24 | $8.7B | — | ||
| Q3 24 | $9.2B | $151.8M | ||
| Q2 24 | $8.9B | — | ||
| Q1 24 | $8.7B | $145.6M |
| Q4 25 | 0.48× | — | ||
| Q3 25 | 0.50× | — | ||
| Q2 25 | 0.52× | — | ||
| Q1 25 | 0.55× | — | ||
| Q4 24 | 0.53× | — | ||
| Q3 24 | 0.49× | — | ||
| Q2 24 | 0.51× | — | ||
| Q1 24 | 0.53× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $229.9M | — |
| Free Cash FlowOCF − Capex | $215.2M | — |
| FCF MarginFCF / Revenue | 20.5% | — |
| Capex IntensityCapex / Revenue | 1.4% | — |
| Cash ConversionOCF / Net Profit | 1.28× | — |
| TTM Free Cash FlowTrailing 4 quarters | $1.0B | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $229.9M | — | ||
| Q3 25 | $355.1M | — | ||
| Q2 25 | $343.3M | — | ||
| Q1 25 | $169.4M | — | ||
| Q4 24 | $189.3M | — | ||
| Q3 24 | $367.0M | — | ||
| Q2 24 | $405.8M | — | ||
| Q1 24 | $292.4M | — |
| Q4 25 | $215.2M | — | ||
| Q3 25 | $341.4M | — | ||
| Q2 25 | $330.5M | — | ||
| Q1 25 | $153.9M | — | ||
| Q4 24 | $172.5M | — | ||
| Q3 24 | $350.6M | — | ||
| Q2 24 | $385.3M | — | ||
| Q1 24 | $279.6M | — |
| Q4 25 | 20.5% | — | ||
| Q3 25 | 32.5% | — | ||
| Q2 25 | 32.3% | — | ||
| Q1 25 | 15.3% | — | ||
| Q4 24 | 16.9% | — | ||
| Q3 24 | 35.5% | — | ||
| Q2 24 | 38.1% | — | ||
| Q1 24 | 27.5% | — |
| Q4 25 | 1.4% | — | ||
| Q3 25 | 1.3% | — | ||
| Q2 25 | 1.3% | — | ||
| Q1 25 | 1.5% | — | ||
| Q4 24 | 1.6% | — | ||
| Q3 24 | 1.7% | — | ||
| Q2 24 | 2.0% | — | ||
| Q1 24 | 1.3% | — |
| Q4 25 | 1.28× | — | ||
| Q3 25 | 1.90× | — | ||
| Q2 25 | 1.76× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.94× | — | ||
| Q3 24 | 2.05× | — | ||
| Q2 24 | 2.09× | — | ||
| Q1 24 | 1.72× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
HOLX
| Molecular Diagnostics | $255.3M | 24% |
| Breast Imaging | $219.9M | 21% |
| Services | $216.4M | 21% |
| Capital Equipment Componentsand Software | $187.2M | 18% |
| Cytology Perinatal | $76.0M | 7% |
| Interventional Breast Solutions | $71.2M | 7% |
| Blood Screening | $8.4M | 1% |
| Other Typeof Revenue | $5.4M | 1% |
VFS
| Sales of vehicles | $662.9M | 92% |
| Sales of spare parts and components | $41.3M | 6% |
| Revenue from leasing activities | $12.3M | 2% |
| Finance income | $2.4M | 0% |
| Rendering of services | $1.2M | 0% |
